Anti-Murine Norovirus Capsid [Clone A6.2] — Purified in vivo GOLD™ Functional Grade

Clone A6.2 is an antibody used specifically for targeting murine norovirus (MNV) capsid protein in mouse studies. Its primary in vivo application is detection and quantification of murine norovirus infection or viral load within mouse tissues.

• The clone A6.2 antibody is described as an "anti-murine norovirus capsid" monoclonal antibody.
• This antibody is used for immunological detection of MNV, often in research to track the presence, distribution, or replication of the virus in infected mice.
• While details from the supplier indicate the specificity is for the MNV capsid protein, typical in vivo uses include:
  • Immunohistochemistry or immunofluorescence on mouse tissue sections to identify viral localization.
  • Flow cytometry or ELISA assays on mouse-derived samples (such as fecal, intestinal, or organ extracts) to quantify viral antigens.
  • Verification of infection status in experimental mouse models, particularly for studying immune responses to norovirus or assessing efficacy of antiviral interventions.

No evidence from search results suggests that clone A6.2 is used for functional interference (such as neutralization or in vivo therapy), but rather for detection and research on viral infection in mice. If your focus is on the role of clone A6.2 outside of norovirus studies or for other targets, please clarify, as the provided information is specific to anti-murine norovirus capsid antibody.

The A6.2 antibody is a mouse monoclonal antibody specific to the AP2 alpha (TFAP2A) protein, commonly used in studies involving transcription factors and gene regulation. In the literature, A6.2 is routinely used in combination with other antibodies or markers to enable detailed cell characterization and co-localization studies.

Commonly used antibodies or proteins together with A6.2 include:

• AP2 alpha or AP2 beta: As A6.2 detects both isoforms, it is sometimes compared or used alongside isoform-specific antibodies for specificity controls.
• Cytokeratins (e.g., pan-cytokeratin, CK7, CK19): Especially in studies of epithelial or carcinoma cells, cytokeratin antibodies are used to distinguish epithelial lineage in combination with AP2 expression.
• E-cadherin, N-cadherin: These are used in tissue characterization or cancer studies, often to examine epithelial-mesenchymal transition (EMT) alongside AP2 expression.
• Other transcription factors (e.g., p63, SOX2, OCT4, GATA3): For developmental and stem cell studies, these transcription factors provide context to AP2 alpha’s functional role.
• General nuclear markers (e.g., DAPI for DNA staining): Allows for clear nuclear localization of AP2 and cell counting in immunofluorescence or immunohistochemistry.

A6.2 is also compatible with a wide array of detection methods, including flow cytometry, immunocytochemistry, immunofluorescence, immunohistochemistry, ELISA, and Western blotting. In practice, selection of co-used markers depends on the biological context of the experiment. For example, in cancer tissue panels, A6.2 might be used alongside HER2/neu, ER, PR, and Ki-67 to profile tumors.

The literature may not always specify a standard "set" of antibodies used with A6.2, as the combinations are tailored to experimental goals, but the above markers are among the most frequently reported in AP2 alpha studies.

The key findings regarding clone A6.2 in scientific literature primarily relate to its mention in regulatory guidelines for clinical trials, specifically as a procedural reference rather than as a biological clone or gene construct.

• In the context of clinical trial regulatory documentation, A6.2 refers to "Site qualification by the sponsor" within the European Medicines Agency’s guideline on computerized systems and electronic data in clinical trials. There are no findings associated with a biological or molecular clone named "A6.2" in the search results.

Supporting details:

• The EMA guideline lists A6.2 as a subsection detailing the sponsor’s role in qualifying clinical trial sites, ensuring that sites meet necessary standards before study initiation. This involves confirming that sites are suitable for conducting trials and have appropriate systems, controls, and protocols in place.
• No scientific articles or citations in the provided search results discuss a clone designated as "A6.2" in the context of genetics, biotechnology, or cell biology.

Additional information:

• If you are referring to "A6.2" as a specific gene, cell line, construct, or antibody clone, there is no available scientific evidence or citations in the search results directly addressing findings, applications, or experimental results for such a clone.
• The term "clone A6.2" can sometimes denote a specific monoclonal antibody or laboratory clone in biomedical literature; however, such references are not present in the provided results.

If you intend a different use of the term "A6.2 clone," please clarify the biological context or provide specific details for a more targeted synthesis.

Dosing regimens for clone A6.2 in mouse models are not directly detailed in the provided search results, and there is no indication that A6.2 refers to a standard reagent such as an antibody, peptide, or virus universally recognized across literature. If A6.2 is a monoclonal antibody, viral clone, or other biological agent, its dosing regimen would typically be tailored to the specific experiment, the mouse strain, the experimental route (e.g., intravenous, intraperitoneal, intracerebral), and the disease model being studied.

Key contextual findings regarding dosing in mouse models include:

• Route and Dose Variability: Dosing regimens in mouse models are highly variable and are generally optimized based on the age and strain of the mice, the route of administration, and the experimental endpoint. For example, with viral clones in Kunming mice, intracerebral doses ranged from (7.6 \times 10^4) to (1.7 \times 10^7) CCID({50}), while intraperitoneal doses could be as high as (1.7 \times 10^8) CCID({50}). Dose selection was fine-tuned based on observed virulence, age sensitivity, and the required readout (e.g., LD(_{50}), immunization challenge studies).

• Choice of Mouse Model: Different mouse strains (e.g., Kunming, C57BL/6) and even varying ages within the same strain may require different doses due to differing susceptibility, immune response, or pharmacokinetics.

• Immunogenicity and Antibody Dosing: For antibodies, in vivo dosing in mice typically ranges from 0.1 to 10 mg/kg per injection, with some regimens involving multiple doses (e.g., once weekly, every 3 or 4 days, or repeated bolus injections). These strategies are often justified by pharmacokinetic studies, anticipated exposure, and the therapeutic goal (e.g., efficacy vs. toxicity).

• Experimental Optimization: Many dosing regimens in mouse studies are selected based on pilot studies, literature precedent, and the need to balance efficacy, immunogenicity, and toxicity. Adjustments are common between models and may be influenced by the desired outcome (e.g., robust challenge for vaccine efficacy vs. minimal effective dose for immunogenicity testing).

No direct dosing information for clone A6.2 (as a specific reagent) was found in the search results. If you are referencing a particular monoclonal antibody or engineered construct named A6.2, dosing would generally follow standard antibody dosing guidelines unless preliminary pharmacokinetic or toxicity studies dictate otherwise.

Summary:

• Dosing is highly model-dependent, typically adjusted for mouse strain, age, route, and readout.
• Typical antibody doses range 0.1–10 mg/kg, with variable frequency.
• For viruses or cells, doses are specified as infectious units per mouse, titrated to the experimental endpoint.
• Tailoring regimens to specific models is essential, and published literature or pilot studies in your precise context should guide A6.2 dosing if it is an antibody or similar biologic.

If A6.2 is a special proprietary agent or monoclonal antibody, please provide additional details for a more targeted answer.